Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Oct 17;5(5):701-703.
doi: 10.1016/j.jaccao.2023.05.007. eCollection 2023 Oct.

Endothelin-1: Is it Time to "Biomark" the Cardiac-Tumor-Treatment Nexus in Breast Cancer?

María Valero-Muñoz  1 , Flora Sam  1
Affiliations
Editorial

Endothelin-1: Is it Time to "Biomark" the Cardiac-Tumor-Treatment Nexus in Breast Cancer?

María Valero-Muñoz et al. JACC CardioOncol. .
No abstract available

Keywords: breast cancer; cardiac remodeling; endothelin-1; therapeutic strategies.

PubMed Disclaimer

Conflict of interest statement

Dr Sam is a full-time employee of Eli Lilly and Co and holds a joint, academic appointment at Boston University School of Medicine. This publication is solely from The Sam Lab, Whitaker Cardiovascular Institute at Boston University School of Medicine and has not been funded nor supported by Eli Lilly and Co. This editorial reflects the views of the authors and should not be construed to represent the views or policies of the U.S. Food and Drug Administration nor Eli Lilly and Co. Dr Valero-Muñoz has reported that she has no relationships relevant to the contents of this paper to disclose.

Figures

None
Graphical abstract
See this image and copyright information in PMC

Comment on

References

    1. Yanagisawa M., Kurihara H., Kimura S., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332(6163):411–415. doi: 10.1038/332411a0. - DOI - PubMed
    1. Haryono A., Ramadhiani R., Ryanto G.R.T., Emoto N. Endothelin and the cardiovascular system: the long journey and where we are going. Biology (Basel) 2022;11(5):759. doi: 10.3390/biology11050759. - DOI - PMC - PubMed
    1. Spieker L.E., Noll G., Ruschitzka F.T., Luscher T.F. Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? J Am Coll Cardiol. 2001;37(6):1493–1505. doi: 10.1016/s0735-1097(01)01210-4. - DOI - PubMed
    1. Nambi P., Clozel M., Feuerstein G. Endothelin and heart failure. Heart Fail Rev. 2001;6(4):335–340. doi: 10.1023/a:1011464510857. - DOI - PubMed
    1. Mo R., Yang Y.M., Yu L.T., Tan H.Q., Zhu J. Elevated plasma big endothelin-1 at admission is associated with poor short-term outcomes in patients with acute decompensated heart failure. Front Cardiovasc Med. 2021;8 doi: 10.3389/fcvm.2021.629268. - DOI - PMC - PubMed

Publication types

LinkOut - more resources